Literature DB >> 655118

The treatment of low-renin ("primary") hyperaldosteronism.

J B Ferriss, D G Beevers, K Boddy, J J Brown, D L Davies, R Fraser, D Kremer, A F Lever, J I Robertson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 655118     DOI： 10.1016/0002-8703(78)90132-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  8 in total

1.  Malignant hypertension and asymmetric septal hypertrophy in a 43-year-old black man.

Authors:  J C Rutledge; A Eng; J Silva
Journal:  West J Med       Date:  1986-09

Review 2.  [Modern pharmacological aspects of hyperaldosteronism therapy].

Authors:  M Quinkler; M Reincke
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

Review 3.  Treatment of primary aldosteronism: Where are we now?

Authors:  Asterios Karagiannis
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

4.  ENaC inhibition stimulates Cl- secretion in the mouse cortical collecting duct through an NKCC1-dependent mechanism.

Authors:  Vladimir Pech; Monika Thumova; Young Hee Kim; Diana Agazatian; Edith Hummler; Bernard C Rossier; Alan M Weinstein; Masayoshi Nanami; Susan M Wall
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-11

5.  Sodium and potassium in essential hypertension.

Authors:  A F Lever; C Beretta-Piccoli; J J Brown; D L Davies; R Fraser; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-15

6.  Clinical significance of associated nodular lesions of the adrenal in patients with aldosteronoma.

Authors:  Y Ito; Y Fujimoto; T Obara; T Kodama
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

7.  Captopril before and after spironolactone therapy in primary aldosteronism. Pathogenetic and therapeutical aspects.

Authors:  M Stimpel; W Vetter; H Groth; P Greminger; H Vetter
Journal:  Klin Wochenschr       Date:  1985-04-15

8.  Hormones other than aldosterone may contribute to hypertension in 3 different subtypes of primary aldosteronism.

Authors:  Fei Ye; Zheng-Yi Tang; Jing-Cheng Wu; Yang Yang; Xiu-Li Tian; Jia-Jia Huang; Shan-Shan Zhang; Guang Ning
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-27       Impact factor: 3.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.